$1,200,000 awarded for ALS research
The following are current research projects that are looking for individuals to participate, in order to better understand different components of ALS that will help develop effective treatments and a better understanding of the disease moving forward. Active Against ALS is sharing these opportunities as a resource and should not be interpreted as an endorsement by our organization.
NIH-FUNDED OBSERVATIONAL ALS RESEARCH
We’re thrilled to share an exciting opportunity for individuals to participate in NIH-funded observational ALS research. The ALL ALS Consortium is dedicated to advancing our understanding of ALS through 2 key studies: ASSESS and PREVENT.
The ASSESS ALL ALS study is currently enrolling people living with ALS, as well as “control” participants - often family members, caregivers, and friends.
The PREVENT ALL ALS study has reached its enrollment goal for individuals genetically at risk for ALS; no new enrollments are being accepted as of September 30, 2026.
The main objectives of these studies are to increase access to research among the ALS community by providing remote enrollment options, strengthen community engagement, and redefine how clinical progression is measured to ensure it reflects what matters to those living with ALS.
The program has plans to build and maintain 2 connected central repositories to store the largest collection of ALS-related clinical data and biological samples. These resources will be shared with researchers to accelerate scientific discoveries and the development of more effective ALS treatments.
To learn more, you can visit all-als.org, email the Patient Communications Department at [email protected].
Or, contact the ALL ALS local site coordinator at the University of Michigan Pranger ALS Clinic, Carli Piecuch at [email protected] or (734) 936-8781. Alternatively, you may contact the local site coordinator at Henry Ford Health in Detroit, Maria Stotland at (313) 916-3359 or [email protected].
The ASSESS ALL ALS study is currently enrolling people living with ALS, as well as “control” participants - often family members, caregivers, and friends.
The PREVENT ALL ALS study has reached its enrollment goal for individuals genetically at risk for ALS; no new enrollments are being accepted as of September 30, 2026.
The main objectives of these studies are to increase access to research among the ALS community by providing remote enrollment options, strengthen community engagement, and redefine how clinical progression is measured to ensure it reflects what matters to those living with ALS.
The program has plans to build and maintain 2 connected central repositories to store the largest collection of ALS-related clinical data and biological samples. These resources will be shared with researchers to accelerate scientific discoveries and the development of more effective ALS treatments.
To learn more, you can visit all-als.org, email the Patient Communications Department at [email protected].
Or, contact the ALL ALS local site coordinator at the University of Michigan Pranger ALS Clinic, Carli Piecuch at [email protected] or (734) 936-8781. Alternatively, you may contact the local site coordinator at Henry Ford Health in Detroit, Maria Stotland at (313) 916-3359 or [email protected].
LEARN MORE @ WWW.ALL-ALS.ORG
|
|
MICHIGAN MEDICINE OPPORTUNITY
EMORY UNIVERSITY OPPORTUNITY
|
Emory University is looking for participants who have undergone genetic testing in regard to
Amyotrophic Lateral Sclerosis-Frontotemporal Dementia (ALS-FTD) spectrum disorders. This study is looking at the factors that influence familial communication of genetic test results in the ALS-FTD spectrum disorders community. This is a one-time, anonymous survey that takes approximately 20-25 minutes to complete. Who Can Participate?
To participate, click here. For questions, contact Liana Kendrick at [email protected] |
Active Against ALS
2232 S. Main Street #323 Ann Arbor, MI 48103 |
|